EUCOPE

The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) is Europe’s trade body that gives a bigger voice to small and mid-sized innovative companies working in the field of biopharmaceuticals and medical technologies. Through its members, EUCOPE represents 2600+ biopharmaceutical companies that are researching, designing, developing, supplying, manufacturing, and deploying the next generation of pharmaceutical innovation and therapeutic solutions around the continent.

Based in Brussels, Belgium, EUCOPE’s commitment is to lead and engage in partnerships spanning the entire medicine lifecycle to find actionable solutions that benefit our members, the patients they serve, and healthcare systems overall. As a trade association, we advocate for sound public policy that supports innovation, while fostering a community built on a shared purpose: improving and saving the lives of European patients through ground-breaking therapies and medical technology. We provide a platform fo

Address

Rue Marie de Bourgogne 58 1000 Brussels Belgium

+32 2 842 69 82
https://www.eucope.org/

Close
EUCOPE

Featured
How the EU can strengthen pharmaceutical competitiveness Partner Content
How the EU can strengthen pharmaceutical competitiveness
03 Oct EU Institutions
by Alexander Natz
By prioritising competitiveness and regulatory efficiency, the EU can empower its pharmaceutical sector to innovate and excel, addressing rare diseases and unmet needs.
Articles
Reform of Pharmaceutical Legislation: A Vision for a Competitive and Compassionate EU Partner Content
10 Jan
Reform of Pharmaceutical Legislation: A Vision for a Competitive and Compassionate EU
In the face of ongoing global challenges, securing the future of Europe's healthcare systems is paramount to future success
The importance of a strong and predictable rare disease ecosystem for the growth of small and mid-sized innovative companies: the case of AOP Health Partner Content
04 Oct
The importance of a strong and predictable rare disease ecosystem for the growth of small and mid-sized innovative companies: the case of AOP Health
Highlighting a Truly European Enterprise: The Imperative for a Competitive EU Pharmaceutical Framework.
Smaller pharmaceutical companies can play an important role in patient centered care: we need them onboard Partner Content
20 Sep
Smaller pharmaceutical companies can play an important role in patient centered care: we need them onboard
In the European Union, the pursuit of a healthcare system that offers both access to life-saving treatments and fosters innovation in pharmaceuticals is an ongoing challenge. Striking the right balance between these two critical objectives is complex, with various
stakeholders involved. We believe that the cooperation between patients and smaller pharmaceutical companies can also significantly impact this balance.
Looking out for the little guy: Why we need a competitive EU pharmaceutical framework for small and mid-sized companies Partner Content
06 Sep
Looking out for the little guy: Why we need a competitive EU pharmaceutical framework for small and mid-sized companies
The EU must provide enough and predictable incentives to encourage innovation and reward investments in the European Pharmaceutical market.
Thoughtful Calibration
02 Mar
Thoughtful Calibration
By fostering collaboration between different stakeholders such as industry, patients, and ERNs, among others, we can develop novel therapies and address the unmet needs, writes Alexander Natz
Learning from the rare disease community Partner Content
25 Feb
Learning from the rare disease community
Europe’s pharmaceutical entrepreneurs are taking the lessons learned from this community to develop health innovation which would not have been dreamt of a few decades ago
Rare Diseases: Celebrating patient-centred innovation Partner Content
26 Feb
Rare Diseases: Celebrating patient-centred innovation
After a challenging year, Rare Disease Day 2021 is a wonderful opportunity to recognise the incredible efforts and achievements of patients, their associations and the scientific community, explains Alexander Natz.